Penumbra Net Profit Margin Growth & History (PEN)
Penumbra's net profit margin was 12.66% for fiscal 2025.
View full Penumbra company overviewPenumbra annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 12.66% | +11.49 pp |
| 2024 | 2024-12-31 | 1.17% | −7.42 pp |
| 2023 | 2023-12-31 | 8.59% | +8.83 pp |
| 2022 | 2022-12-31 | −0.24% | −0.94 pp |
| 2021 | 2021-12-31 | 0.71% | +3.51 pp |
| 2020 | 2020-12-31 | −2.80% | −11.65 pp |
| 2019 | 2019-12-31 | 8.85% | +7.37 pp |
| 2018 | 2018-12-31 | 1.48% | +0.09 pp |
| 2017 | 2017-12-31 | 1.40% | −4.23 pp |
| 2016 | 2016-12-31 | 5.63% | +4.36 pp |
| 2015 | 2015-12-31 | 1.27% | −0.52 pp |
| 2014 | 2014-12-31 | 1.79% | −2.82 pp |
| 2013 | 2013-12-31 | 4.61% | — |
Penumbra quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 8.92% | −4.41 pp |
| Q1 2026 | 2026-03-31 | 8.69% | −3.41 pp |
| Q4 2025 | 2025-12-31 | 12.28% | +1.61 pp |
| Q3 2025 | 2025-09-30 | 12.93% | +3.12 pp |
| Q2 2025 | 2025-06-30 | 13.34% | +33.44 pp |
| Q1 2025 | 2025-03-31 | 12.10% | +8.15 pp |
| Q4 2024 | 2024-12-31 | 10.68% | −8.37 pp |
| Q3 2024 | 2024-09-30 | 9.81% | +6.41 pp |
| Q2 2024 | 2024-06-30 | −20.11% | −27.36 pp |
| Q1 2024 | 2024-03-31 | 3.95% | +0.40 pp |
| Q4 2023 | 2023-12-31 | 19.05% | +17.29 pp |
| Q3 2023 | 2023-09-30 | 3.40% | +4.46 pp |
| Q2 2023 | 2023-06-30 | 7.25% | +9.02 pp |
| Q1 2023 | 2023-03-31 | 3.55% | +3.51 pp |
| Q4 2022 | 2022-12-31 | 1.75% | +13.83 pp |
| Q3 2022 | 2022-09-30 | −1.06% | −5.72 pp |
| Q2 2022 | 2022-06-30 | −1.77% | −6.78 pp |
| Q1 2022 | 2022-03-31 | 0.04% | −6.96 pp |
| Q4 2021 | 2021-12-31 | −12.07% | −14.26 pp |
| Q3 2021 | 2021-09-30 | 4.66% | +10.49 pp |
| Q2 2021 | 2021-06-30 | 5.01% | +16.39 pp |
| Q1 2021 | 2021-03-31 | 7.00% | +5.96 pp |
| Q4 2020 | 2020-12-31 | 2.19% | −4.48 pp |
| Q3 2020 | 2020-09-30 | −5.83% | −14.07 pp |
| Q2 2020 | 2020-06-30 | −11.38% | −23.74 pp |
| Q1 2020 | 2020-03-31 | 1.04% | −7.29 pp |
| Q4 2019 | 2019-12-31 | 6.67% | +1.16 pp |
| Q3 2019 | 2019-09-30 | 8.23% | +25.16 pp |
| Q2 2019 | 2019-06-30 | 12.36% | +0.16 pp |
| Q1 2019 | 2019-03-31 | 8.33% | +2.98 pp |
| Q4 2018 | 2018-12-31 | 5.51% | −3.94 pp |
| Q3 2018 | 2018-09-30 | −16.93% | −17.21 pp |
| Q2 2018 | 2018-06-30 | 12.20% | +14.14 pp |
| Q1 2018 | 2018-03-31 | 5.35% | +9.59 pp |
| Q4 2017 | 2017-12-31 | 9.46% | +12.73 pp |
| Q3 2017 | 2017-09-30 | 0.28% | −17.44 pp |
| Q2 2017 | 2017-06-30 | −1.93% | −6.56 pp |
| Q1 2017 | 2017-03-31 | −4.24% | −8.20 pp |
| Q4 2016 | 2016-12-31 | −3.28% | −6.28 pp |
| Q3 2016 | 2016-09-30 | 17.72% | +15.93 pp |
| Q2 2016 | 2016-06-30 | 4.63% | +10.94 pp |
| Q1 2016 | 2016-03-31 | 3.96% | −2.47 pp |
| Q4 2015 | 2015-12-31 | 3.00% | +1.83 pp |
| Q3 2015 | 2015-09-30 | 1.79% | +1.26 pp |
| Q2 2015 | 2015-06-30 | −6.31% | −7.55 pp |
| Q1 2015 | 2015-03-31 | 6.42% | +1.58 pp |
| Q4 2014 | 2014-12-31 | 1.18% | — |
| Q3 2014 | 2014-09-30 | 0.53% | — |
| Q2 2014 | 2014-06-30 | 1.24% | — |
| Q1 2014 | 2014-03-31 | 4.84% | — |
Penumbra net profit margin trends
Over the last five fiscal years, Penumbra's net profit margin increased from −2.80% to 12.66%, a change of +15.46 percentage points. The latest reported quarter, Q2 2026, shows 8.92%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Penumbra source filings ↗Community posts
Penumbra’s thrombectomy business leads 16% quarterly sales growth
Penumbra ($PEN) reported third-quarter 2026 revenue of $410.1 million, up 15.6%, as demand for its clot-removal systems expanded. Thrombectomy sales increased 18.1% to $279.2 million, including 26% growth in the US venous-thromboembolism bu ...